Scientific Publications & PhD Theses

  • The convergent epidemiology of tuberculosis and human cytomegalovirus infection

    Authored by: Frank Cobelens, Nico Nagelkerke, Helen Fletcher
    Journal: F1000Research
    Research Priority: Infectious Disease Elimination

    DOI: 10.12688/f1000research.14184.2

  • Clinical bacteriology in low-resource settings: today’s solutions

    Authored by: Sien Ombelet*, Jean-Baptiste Ronat*, Timothy Walsh, Cedric P Yansouni, Janneke Cox, Erika Vlieghe, Delphine Martiny, Makeda Semret, Olivier Vandenberg, Jan Jacobs, on behalf of the Bacteriology in Low Resource Settings working group† (With contribution from Constance Schultsz)
    Journal: The Lancet Infectious Diseases
    Research Priority Areas: Antimicrobial Drug Resistance

    *Contributed equally
    † Members listed in the contributors section

  • Double for Nothing? Experimental Evidence on an Unconditional Teacher Salary Increase in Indonesia

    Authored by: Joppe de Ree, Karthik Muralidharan, Menno Pradhan, Halsey Rogers
    Journal: The Quarterly Journal of Economics, Volume 133, Issue 2, 1 May 2018, Pages 993–1039
    Research Priority Areas: Economics of Human Development

  • The impact of subsidized private health insurance and health facility upgrades on healthcare utilization and spending in rural Nigeria

    Authored by: Emily Gustafsson-Wright, Gosia Popławska, Zlata Tanović, Jacques van der Gaag
    Journal: Int J Health Econ Manag (online)
    Research Priority Areas: Economics of Human Development, Health Markets

  • Reflections on a community engagement strategy for mass antimalarial drug administration in western Cambodia

    Authored by: Thomas J. Peto, Rupam Tripura, Chan Davoeung, Chea Nguon, Sanann Nou, Chhouen Heng, Pich Kunthea, Bipin Adhikari1, Renly Lim, Nicola James, Christopher Pell, Phaik Yeong Cheah
    Journal: American Journal of Tropical Medicine & Hygiene 98 (1): 100-104
    Research Priority Area: Infectious Disease Elimination

  • Prevention of malaria in pregnancy

    Authored by: Meghna Desai, Jenny Hill, Silke Fernandes, Patrick Walker, Christopher Pell, Julie Gutman, Kassoum Kayentao, Raquel Gonzalez, Prof Jayne Webster, Prof Brian Greenwood, Michel Cot, Prof Feiko O ter Kuile,
    Journal: Lancet Infectious Disease
    Research Priority Area: Infectious Disease Elimination

  • Treatment of uncomplicated and severe malaria during pregnancy

    Authored by: Umberto D’Alessandro, Jenny Hill, Joel Tarning, Christopher Pell, Jayne Webster, Julie Gutman, Esperanca Sevene
    Journal: Lancet Infectious Disease
    Research Priority Area: Infectious Disease Elimination

  • Community participation during two mass anti-malarial administrations in Cambodia: lessons from a joint workshop

    Authored by: Thomas J. Peto, Mark Debackere, William Etienne, Lieven Vernaeve, Rupam Tripura, Gregoire Falq, Chan Davoeung, Chea Nguon, Huy Rekol, Lorenz von Seidlein, Arjen M. Dondorp, Nou Sanann, Phaik Yeong Cheah, Martin De Smet, Christopher Pell and Jean-Marie Kindermans
    Journal: Malaria Journal
    Research Priority Area: Infectious Disease Elimination

  • False starts in ‘test and start’: a qualitative study of reasons for delayed anti-retroviral therapy in Swaziland

    Authored by: Christopher Pell, Eva Vernooij, Nelisiwe Masilela, Njabulo Simelane, Fortunate Shabalala, Ria Reis
    Journal: International Health
    Research Priority Area: Infectious Disease Elimination

  • Why do people participate in mass anti-malarial administration? Findings from a qualitative study in Nong District, Savannakhet Province, Lao PDR (Laos)

    Authored by: Bipin Adhikari, Koukeo Phommasone, Palingnaphone Kommarasy, Xayaphone Soundala, Phonesavanh Souvanthong, Tiengkham Pongvongsa, Gisela Henriques, Paul N. Newton, Nicholas J. White, Nicholas P. J. Day, Arjen M. Dondorp, Lorenz von Seidlein, Mayfong Mayxay, Phaik Yeong Cheah and Christopher Pell
    Journal: Malaria Journal
    Research Priority Area: Infectious Disease Elimination

  • The effect of health insurance and health facility-upgrades on hospital deliveries in rural Nigeria: a controlled interrupted time-series study

    Authored by: Daniëlla Brals, Sunday A Aderibigbe, Ferdinand W Wit, Johannes C M van Ophem, Marijn van der List, Gordon K Osagbemi, Marleen E Hendriks, Tanimola M Akande, Michael Boele van Hensbroek, Constance Schultsz

    Health Policy and Planning, Volume 32, Issue 7, 1 September 2017, Pages 990–1001

    Access to quality obstetric care is considered essential to reducing maternal and new-born mortality. We evaluated the effect of the introduction of a multifaceted voluntary health insurance programme on hospital deliveries in rural Nigeria.

  • HIV screening at health facilities and community pharmacies in Kenya: enhancing test uptake and early diagnosis

    Authored by: Peter Mugo
    Thesis Universiteit van Amsterdam
    Promotor(s): T.F. Rinke de Wit
    Date of thesis defense: 13/10/2017

    Despite a tremendous scale-up of antiretroviral therapy, as many as 54% of HIV-infected persons globally remain undiagnosed hence are not on treatment. This thesis presents findings from a series of studies conducted in Coastal Kenya aiming to enhance HIV test uptake and early diagnosis. Read more

  • Antimicrobial drug resistance at the human-animal interface in Vietnam

    Authored by: Trung Nguyen Vinh
    Thesis Universiteit van Amsterdam
    Promotor(s): C. Schultsz
    Date of thesis defense: 13/09/2017

    This thesis investigates the prevalence of antimicrobial resistance (AMR) among non-typhoidal Salmonella (NTS) and E. coli strains isolated from backyard farm chickens and humans in Vietnam. We found that this prevalence was to some extent related to antimicrobial usage. Read more

  • Consequences of Mycobacterium tuberculosis genetic diversity in the context of HIV co-infection for laboratory diagnosis of tuberculosis in Africa

    Authored by: Willy Ssengooba
    Thesis Universiteit van Amsterdam
    Promotor(s): F.G.J. Cobelens
    Copromotor(s): F.C.M. van Leth
    Date of thesis defense: 13/09/2017

    Willy Ssengooba’s thesis evaluates the consequences of the genetic diversity of Mycobacterium tuberculosis, the causative agent of tuberculosis, for diagnosis of this disease tuberculosis in Africa, often in HIV co-infected patients. It addresses three main sub-themes around M. tuberculosis genetic diversity; laboratory diagnosis, clinical presentation of tuberculosis disease and resistance to anti-tuberculosis drugs. Read more


  • Healthcare Quality in Ghana Improving healthcare quality and health worker motivation to promote sustainable health insurance

    Authored by: Robert Kaba Alhassan
    Thesis Universiteit van Amsterdam
    Promotor(s): T.F. Rinke de Wit
    Date of thesis defense: 01/05/2017

    This thesis is about promoting a sustainable National Health Insurance Scheme (NHIS) in Ghana through improved client-centred quality care and effective community engagement in quality care assessment. Read more

  • Point-of-care diagnostic tools: Selection, evaluation and implementation in resource constrained settings

    Authored by: Cara Kosack
    Thesis Universiteit van Amsterdam
    Promotor(s): P.R. Klatser
    Date of thesis defense: 04/04/2017

    In recent year’s point-of-care diagnostic tools especially for the three main killer diseases HIV/AIDS, tuberculosis and malaria have been emerging on the market. Read more

  • Evaluating the effectiveness of interventions for the prevention of tuberculosis in a low-incidence setting

    Authored by: Connie Erkens
    Thesis Universiteit van Amsterdam
    Promotor(s): F.G.J. Cobelens
    Date of thesis defense: 29/03/2017

    The thesis presents studies into the effectiveness of specific tuberculosis (TB) control interventions in the Netherlands aimed at early case finding and prevention of TB. The first study showed screening of new immigrants upon entry met the criteria for risk group screening of more than 50 per 100,000 population. Read more

  • Prevention, Suppression, and Resistance: Antiretroviral Treatment for Children with HIV in Sub-Saharan Africa

    Authored by: Ragna Boerma
    Thesis Universiteit van Amsterdam
    Promotor(s): T.F. Rinke de Wit
    Copromotor(s): M. Boele van Hensbroek
    Date of thesis defense: 24/03/2017

    This thesis describes the virological and clinical outcomes of children with HIV in sub-Saharan Africa who start antiretroviral treatment (ART). We show that pretreatment HIV drug resistance among children is a serious problem in sub-Saharan Africa and that its prevalence is increasing. Children who start first-line ART have much lower virological suppression rates compared to adults and data on long-term treatment outcomes of these children are largely missing. Read more

  • Head and heart in treated HIV infection

    Authored by: Judith Schouten
    Thesis Universiteit van Amsterdam
    Promotor(s): P. Reiss
    Copromotor(s): F.W.N.M. Wit and M. van der Valk
    Date of thesis defense: 27/01/2017

    The introduction of combination antiretroviral therapy (cART) in 1996 changed HIV infection from an inevitably fatal condition into a chronic manageable disease. During the last decade however, concerns have been raised about the increasingly important role of non-AIDS comorbidities as causes of death in cART-treated patients and a potential excess prevalence of non-AIDS comorbidities among HIV-infected individuals. Read more

  • Comorbidity and ageing in HIV infection

    Authored by: Katherine Kooij
    Thesis Universiteit van Amsterdam
    Promotor(s): P. Reiss
    Copromotor(s): F.W.N.M. Wit
    Date of thesis defense: 27/01/20175

    In the era of modern combination antiretroviral therapy (cART) the HIV-infected population is ageing. Studies have suggested that HIV-infected individuals, even if appropriately treated with cART, may be at increased risk for several age-related conditions. Read more



  • Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure

    Authored by: Dedicoat MJ, Günther G, Crudu V, Duarte R, Gualano G, Magis-Escurra C, Rumetshofer R, Skrahina A, Spinu V, Tiberi S, Viiklepp P, van Leth F, Lange C; TBNET.
    Am J Respir Crit Care Med. 2017 Mar 21. doi: 10.1164/rccm.201612-2585LE. [Epub ahead of print] No abstract available.

  • Rapid assessment of antimicrobial resistance prevalence using a Lot Quality Assurance sampling approach

    Authored by: van Leth F, den Heijer C, Beerepoot M, Stobberingh E, Geerlings S, Schultsz C.
    Future Microbiol. 2017 Mar 24. doi: 10.2217/fmb-2016-0170. [Epub ahead of print]

  • Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review.

    Authored by: Bruins WS, van Leth F.
    Infect Dis (Lond). 2017 Mar;49(3):161-169. doi: 10.1080/23744235.2016.1262059.

  • Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial

    Authored by: Manabe YC, Worodria W, van Leth F, Mayanja-Kizza H, Traore AN, Ferro J, Pakker N, Frank M, Grobusch MP, Colebunders R, Cobelens F.
    Am J Trop Med Hyg. 2016 Dec 7;95(6):1265-1271.

  • More on Treatment Outcomes in Multidrug-Resistant Tuberculosis

    Authored by: Lange C, Günther G, van Leth F; TBNET.
    N Engl J Med. 2016 Dec 29;375(26):2611. doi: 10.1056/NEJMc1613123. No abstract available.

  • Antimicrobial resistance in uropathogens and appropriateness of empirical treatment: a population-based surveillance study in Indonesia

    Authored by: Sugianli AK, Ginting F, Kusumawati RL, Pranggono EH, Pasaribu AP, Gronthoud F, Geerlings S, Parwati I, De Jong MD, Van Leth F, Schultsz C.
    J Antimicrob Chemother. 2017 Jan 30. pii: dkw578. doi: 10.1093/jac/dkw578. [Epub ahead of print]

  • Increased brain-predicted aging in treated HIV disease

    Authored by: James H. Cole, PhD; Jonathan Underwood, MBBS, BSc; Matthan W.A. Caan, PhD; Davide De Francesco, MSc; Rosan A. van Zoest, MD; Robert Leech, PhD; Ferdinand W.N.M. Wit, PhD; Peter Portegies, PhD; Gert J. Geurtsen, PhD; Ben A. Schmand, PhD; Maarten F. Schim van der Loeff, PhD; Claudio Franceschi, PhD; Caroline A. Sabin, PhD;  Charles B.L.M. Majoie, MD, PhD; Alan Winston, MD, PhD; Peter Reiss, MD, PhD; David J. Sharp, PhD. On behalf of the COBRA collaboration.
    In: Neurology. DOI: 10.1212/WNL.0000000000003790

  • Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts

    Authored by: Rimke Bijker, Awachana Jiamsakul, Cissy Kityo, Sasisopin Kiertiburanakul, Margaret Siwale, Praphan Phanuphak, Sulaimon Akanmu, Romanee Chaiwarith, Ferdinand W Wit, Benedict LH Sim, Tamara Sonia Boender, Rossana Ditangco, Tobias F Rinke de Wit, Annette H Sohn, Raph L Hamers.
    In: Journal of the International AIDS Society 2017, 20:21218

    Our understanding of how to achieve optimal long-term adherence to antiretroviral therapy (ART) in settings where the burden of HIV disease is highest remains limited. We compared levels and determinants of adherence over time between HIV-positive persons receiving ART who were enrolled in a bi-regional cohort in sub-Saharan Africa and Asia.

  • Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study

    Authored by: Helen Cox, Lindy Dickson-Hall, Norbert Ndjeka, Anja van’t Hoog, Alison Grant, Frank Cobelens, Wendy Stevens, Mark Nicol.
    In: PLoS Med 14(2): e1002238. doi:10.1371/journal.pmed.1002238

    South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,734 patients diagnosed in 2014. The number of diagnosed patients has increased substantially with the introduction of the Xpert MTB/RIF test, used for tuberculosis (TB) diagnosis for all patients with presumptive TB. Routine aggregate data suggest a large treatment gap (pre-treatment loss to follow-up) between the numbers of patients with laboratory-confirmed RR-TB and those reported to have started second-line treatment. We aimed to assess the impact of Xpert MTB/RIF implementation on the delay to treatment initiation and loss to follow-up before second-line treatment for RR-TB across South Africa.

  • The evolving landscape of HIV drug resistance diagnosis for expanding testing in resource-limited settings.

    Authored by: Inzaule, S.C., Hamers, R.L., Paredes, R., Yang, C., Schuurman, R. and Rinke de Wit, T.F.
    In: AIDS Reviews, in press, 2017.

  • Uptake and acceptability of oral HIV Self-Testing among community pharmacy clients in Kenya: a feasibility study

    Authored by: Mugo, P., Micheni, M., Shangala, J., Hanif, M., Graham, S., Rinke de Wit, T.F., and Sanders, E.
    In: PLOS One, in press, 2017.

  • Determinants of adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts

    Authored by: Bijker, R., Jiamsaku, A., Kityo, C.M., Kiertiburanakul, S., Siwale, M., Phanuphak, P., Akanmu, S., Chaiwarit, R., Wit, F., Sim, B.L.H., Boender, T.S., Ditangco, R., Rinke de Wit, T.F., Sohn, A.H. and Hamers, R.L. . J.
    In: Int. AIDS Soc., in press, 2017.

  • Cigarette Smoking and Inflammation, Monocyte Activation, and Coagulation in HIV-Infected Individuals Receiving Antiretroviral Therapy, Compared With Uninfected Individuals

    Authored by: Kooij KW, Wit FW, Booiman T, van der Valk M, Schim van der Loeff MF, Kootstra NA, Reiss P; AGEhIV Cohort Study Group.
    In: J Infect Dis. 2016 Dec 15;214(12):1817-1821.

    Smoking may affect cardiovascular disease risk more strongly in human immunodeficiency virus (HIV)-infected individuals than HIV-uninfected individuals. We hypothesized that an interaction at the level of the immune system may contribute to this increased risk. We assessed soluble markers of inflammation (high-sensitivity C-reactive protein [hsCRP]), immune activation (soluble [s]CD14 and sCD163), and coagulation (D-dimer) in HIV-infected and uninfected never, former, and current smokers. Smoking was independently associated with higher hsCRP levels and lower sCD163 levels and was borderline significantly associated with higher sCD14 and D-dimer levels. We found no evidence of a differential effect of smoking in HIV-infected individuals as compared to uninfected individuals.

  • Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers

    Authored by: Alffenaar JC, Akkerman OW, Anthony RM, Tiberi S, Heysell S, Grobusch MP, Cobelens FG, Van Soolingen D.
    In: Expert Rev Anti Infect Ther 2017;15:11-21.

    Success rates for treatment of extensively drug resistant tuberculosis (XDR-TB) are low due to limited treatment options, delayed diagnosis and inadequate health care infrastructure. Areas covered: This review analyses existing programmes of prevention, diagnosis and treatment of XDR-TB. Improved diagnostic procedures and rapid molecular tests help to select appropriate drugs and dosages. Drugs dosages can be further tailored to the specific conditions of the patient based on quantitative susceptibility testing of the M. tuberculosis isolate and use of therapeutic drug monitoring. Pharmacovigilance is important for preserving activity of the novel drugs bedaquiline and delamanid. Furthermore, biomarkers of treatment response must be developed and validated to guide therapeutic decisions. Expert commentary: Given the currently poor treatment outcomes and the association of XDR-TB with HIV in endemic regions, a more patient oriented approach regarding diagnostics, drug selection and tailoring and treatment evaluation will improve treatment outcome. The different areas of expertise should be covered by a multidisciplinary team and may involve the transition of patients from hospitalized to home or community-based treatment.

  • Assessment of a 96-well plate assay of quantitative drug susceptibility testing for Mycobacterium tuberculosis complex in China

    Authored by: Xia H, Zheng Y, Zhao B, Van den Hof S, Cobelens F, Zhao Y.
    In: PLoS One 2017;12:e0169413.

  • From latent to patent: rethinking prediction of tuberculosis disease in infected individuals

    Authored by: Cobelens F, Kik S, Esmail H, Cirillo DM, Lienhardt C, Matteelli A.
    In: Lancet Resp Med 2016.

    Tuberculosis remains a major global health problem. It is estimated that more than 2 billion people around the world are latently infected with Mycobacterium tuberculosis, with a lifetime risk of progression to tuberculosis disease of 5–15%.1 The WHO End Tuberculosis strategy, which aims to end tuberculosis as a major health problem by 2035, calls for reducing this huge reservoir for transmission by scaling up preventive therapy of individuals with latent tuberculosis infection. Preventive therapy with daily isoniazid offers 60–90% protection and combination therapies (daily isoniazid-rifampicin, weekly isoniazid-rifapentine) are effective alternatives.

    Ankeiler: In this viewpoint paper Frank Cobelens and co-authors propose a new paradigm for understanding testing for latent tuberculosis infection (LTBI). It distinguishes testing for persistent TB infection from testing for very early clinical („incipient”) TB and argues that only tests that belong to the latter category will be sufficiently predictive for clinical tuberculosis developing within a 2-year timeframe to be used for large-scale test-and-treat of LTBI. This notion has implications for the design, evaluation and application of new LTBI tests.

  • It takes more than a sensitive test to find more tuberculosis cases

    Authored by: Trajman A, Cobelens F.
    In: Lancet Infect Dis, 2017 5 Jan.

    Of the 9·6 million people estimated to have developed tuberculosis in 2014, only 63% of cases were reported.1 This gap partly reflects low rates of case detection and calls for models of intensified case finding at the community level based on effective and feasible screening strategies and technologies.

    Ankeiler: In this comment Anete Trajman and Frank Cobelens discuss the limitations of pragmatic trials of enhanced/active case finding for tuberculosis, in particular the sensitivity of the results to variation in existing practice and the importance of cost-effectiveness.

  • Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model

    Authored by: Fofana M, Shrestha S, Knight G, Cohen T, White R, Cobelens F, Dowdy D.
    In: Antimicrob Agents Chemother, 2016 Dec 12. pii: AAC.00498-16.

  • Health Seeking Behaviour among Individuals with Presumptive Tuberculosis in Zambia

    Authored by: Chanda-Kapata P, Kapata N, Masiye F, Maboshe M, Klinkenberg E, Cobelens F, Grobusch MP.
    In: PLoS One 2016;11:e0163975.

  • Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study

    Authored by: The PASER group, Ravi Gupta, Raph Hamers et al.
    In: The Lancet online 2016 November 30,

    HIV-1 drug resistance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been identified in sub-Saharan Africa in patients with virological failure of first-line combination antiretroviral therapy (ART) containing the modern nucleoside reverse transcriptase inhibitor tenofovir. We aimed to investigate the prevalence and correlates of thymidine analogue mutations (TAM) in patients with virological failure of first-line tenofovir-containing ART.

  • Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants

    Authored by: NCD Risk Factor Collaboration (NCD-RisC)*
    In: The Lancet online 2016 November 15, doi: 10.1016/S0140-6736(16)31919-5
    *Hendriks, M. e.a.

    Raised blood pressure is an important risk factor for cardiovascular diseases and chronic kidney disease. We estimated worldwide trends in mean systolic and mean diastolic blood pressure, and the prevalence of, and number of people with, raised blood pressure, defined as systolic blood pressure of 140 mm Hg or higher or diastolic blood pressure of 90 mm Hg or higher.


  • Tradeoffs in Bedaquiline Introduction Policies: A Model Based Analysis

    Authored by: Kunkel A, Cobelens F, Cohen T.
    In: PLoS Med 2016;13:e1002142.

    Bedaquilline, a new drug to treat tuberculosis, is currently only recommended for use in patients with advanced forms of drug resistance (XDR-TB and “pre-XDR-TB’). In a collaboration with Yale School of Public Health we used mathematical modeling to predict the effects of alternative scenarios of introducing bedaquilline. We showed that expanding bedaquiline access to all patients with MDR TB would have the best trade-offs for patients’ health, protection of background MDR TB drugs and reduction in transmission, although it would likely result in greater resistance to bedaquiline. This means that WHO should consider less restrictive use of this drug. Read more

  • Do Xpert MTB/RIF Cycle Threshold Values Provide Information about Patient Delays for Tuberculosis Diagnosis?

    Authored by: Ssengooba W, Respeito D, Mambuque E, Blanco S, Bulo H, Mandomando I, de Jong BC, Cobelens FG, García-Basteiro AL.
    In: PLoS One 2016;11:e0162833.

    In this study done in Mozambique we analyzed whether information about sputum bacterial burden provided by the GeneXpert diagnostic test is associated with diagnostic delays among tuberculosis patients, and could thereby be used to monitor such delays as an indicator of the quality of TB control efforts. We found no such association. Read more

  • Limited Benefit of the New Shorter MDR-TB Regimen in Europe

    Authored by: Lange C, Duarte R, Fréchet-Jachym M, Guenther G, Guglielmetti L, Olaru ID, Oliveira O, Rumetshofer R, Veziris N, van Leth F; European MDR-TB database collaboration.
    In: Am J Respir Crit Care Med. 2016 Sep 29. [Epub ahead of print] No abstract available.

  • Population impact of factors associated with prevalent pulmonary tuberculosis in Tanzania

    Authored by: Senkoro M, Kumar AM, Chinnakali P, Mfinanga SG, Egwaga S, Kamara V, van Leth F, Hinderaker SG.
    In: Int J Tuberc Lung Dis. 2016 Oct;20(10):1326-1333.


  • An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype

    Authored by: Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Nelson M, Montaner JS, Lane HC, Larder BA; RDI Data and Study Group.
    In: J Antimicrob Chemother. 2016 Oct;71(10):2928-37. PMID: 27330070

  • Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa

    Authored by: Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, Siwale M, Nankya I, Kaudha E, Akanmu AS, Botes ME, Steegen K, Calis JC, Rinke de Wit TF, Sigaloff KC.
    In: J Antimicrob Chemother. 2016 Oct;71(10):2918-27. PMID: 27342546

  • Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa

    Authored by: Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, Labib Maksimos EE, Balinda SN, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Stevens W, Rinke de Wit TF, Sigaloff KC.
    In: J Infect Dis. 2016 Sep 15;214(6):873-83. PMID: 27402780

  • Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa

    Authored by: Inzaule SC, Ondoa P, Peter T, Mugyenyi PN, Stevens WS, de Wit TF, Hamers RL.
    In: Lancet Infect Dis. 2016 Aug 25. pii: S1473-3099(16)30118-9. doi: 10.1016/S1473-3099(16)30118-9. PMID: 27569762

  • Next-generation sequencing and HIV drug resistance surveillance

    Authored by: Hamers RL, Paredes R.
    In: Lancet HIV. 2016 Sep 14. pii: S2352-3018(16)30151-5. doi: 10.1016/S2352-3018(16)30151-5. PMID: 27658866